Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Equity Average (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Equity Average for 6 consecutive years, with $76.5 million as the latest value for Q3 2025.

  • Quarterly Equity Average rose 3249.76% to $76.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $76.5 million through Sep 2025, up 3249.76% year-over-year, with the annual reading at $52.9 million for FY2024, 230.63% up from the prior year.
  • Equity Average for Q3 2025 was $76.5 million at Inhibikase Therapeutics, down from $82.9 million in the prior quarter.
  • The five-year high for Equity Average was $90.3 million in Q1 2025, with the low at $2.3 million in Q3 2024.
  • Average Equity Average over 5 years is $33.2 million, with a median of $27.3 million recorded in 2022.
  • The sharpest move saw Equity Average crashed 86.76% in 2024, then surged 3249.76% in 2025.
  • Over 5 years, Equity Average stood at $40.8 million in 2021, then tumbled by 43.4% to $23.1 million in 2022, then plummeted by 43.7% to $13.0 million in 2023, then soared by 262.89% to $47.2 million in 2024, then skyrocketed by 62.14% to $76.5 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $76.5 million, $82.9 million, and $90.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.